Suven Pharmaceuticals Limited (NSE: SUVENPHAR)
India
· Delayed Price · Currency is INR
1,116.65
-13.45 (-1.19%)
Dec 24, 2024, 3:30 PM IST
Suven Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 |
Operating Revenue | 9,612 | 10,514 | 13,403 | 13,202 | 10,097 | 8,338 | Upgrade
|
Other Revenue | - | - | - | - | -0 | - | Upgrade
|
Revenue | 9,612 | 10,514 | 13,403 | 13,202 | 10,097 | 8,338 | Upgrade
|
Revenue Growth (YoY) | -26.16% | -21.56% | 1.52% | 30.75% | 21.10% | -8.05% | Upgrade
|
Cost of Revenue | 4,071 | 4,503 | 5,882 | 5,741 | 4,372 | 3,342 | Upgrade
|
Gross Profit | 5,541 | 6,010 | 7,521 | 7,461 | 5,725 | 4,996 | Upgrade
|
Selling, General & Admin | 1,761 | 1,403 | 1,218 | 1,024 | 784.18 | 695.06 | Upgrade
|
Research & Development | - | - | - | 103.55 | 110.58 | 141.32 | Upgrade
|
Other Operating Expenses | 512.99 | 516.59 | 561.82 | 526.62 | 415.35 | 340.68 | Upgrade
|
Operating Expenses | 2,878 | 2,465 | 2,259 | 2,045 | 1,626 | 1,412 | Upgrade
|
Operating Income | 2,663 | 3,545 | 5,262 | 5,416 | 4,099 | 3,584 | Upgrade
|
Interest Expense | -77.31 | -74.51 | -128.11 | -62.31 | -91.44 | -199.15 | Upgrade
|
Interest & Investment Income | 20.15 | 20.15 | 58.32 | 0.69 | 2.68 | 3.61 | Upgrade
|
Earnings From Equity Investments | - | - | - | 411.12 | 537.36 | 482.13 | Upgrade
|
Currency Exchange Gain (Loss) | 81.23 | 81.23 | 214.38 | 164.21 | 95.59 | 110.37 | Upgrade
|
Other Non Operating Income (Expenses) | 83.53 | 65.83 | 32.9 | 0.02 | 0 | 1.46 | Upgrade
|
EBT Excluding Unusual Items | 2,770 | 3,638 | 5,439 | 5,930 | 4,643 | 3,982 | Upgrade
|
Merger & Restructuring Charges | -32.24 | -32.24 | - | - | - | - | Upgrade
|
Gain (Loss) on Sale of Investments | 449.11 | 449.11 | 156.87 | 636.14 | 33.28 | 62.31 | Upgrade
|
Gain (Loss) on Sale of Assets | -0.68 | -0.68 | -0.07 | 106.03 | 0.34 | 0.58 | Upgrade
|
Other Unusual Items | 2.73 | 2.73 | 1.17 | 3.73 | - | - | Upgrade
|
Pretax Income | 3,189 | 4,057 | 5,597 | 6,676 | 4,677 | 4,045 | Upgrade
|
Income Tax Expense | 760.41 | 1,054 | 1,484 | 2,138 | 1,053 | 875.1 | Upgrade
|
Net Income | 2,431 | 3,003 | 4,113 | 4,538 | 3,623 | 3,170 | Upgrade
|
Net Income to Common | 2,431 | 3,003 | 4,113 | 4,538 | 3,623 | 3,170 | Upgrade
|
Net Income Growth | -43.70% | -26.99% | -9.37% | 25.24% | 14.30% | 20.87% | Upgrade
|
Shares Outstanding (Basic) | 254 | 255 | 255 | 255 | 255 | 255 | Upgrade
|
Shares Outstanding (Diluted) | 255 | 255 | 255 | 255 | 255 | 255 | Upgrade
|
Shares Change (YoY) | 0.10% | - | - | - | -0.00% | 0.00% | Upgrade
|
EPS (Basic) | 9.55 | 11.80 | 16.16 | 17.83 | 14.23 | 12.45 | Upgrade
|
EPS (Diluted) | 9.54 | 11.80 | 16.16 | 17.83 | 14.23 | 12.45 | Upgrade
|
EPS Growth | -43.74% | -26.99% | -9.37% | 25.28% | 14.30% | 20.85% | Upgrade
|
Free Cash Flow | 1,885 | 3,067 | 1,713 | 2,548 | 2,717 | 3,039 | Upgrade
|
Free Cash Flow Per Share | 7.39 | 12.05 | 6.73 | 10.01 | 10.67 | 11.94 | Upgrade
|
Dividend Per Share | - | - | - | 2.000 | 2.000 | 1.250 | Upgrade
|
Dividend Growth | - | - | - | 0% | 60.00% | -30.56% | Upgrade
|
Gross Margin | 57.65% | 57.17% | 56.11% | 56.51% | 56.70% | 59.92% | Upgrade
|
Operating Margin | 27.70% | 33.72% | 39.26% | 41.03% | 40.59% | 42.98% | Upgrade
|
Profit Margin | 25.29% | 28.56% | 30.69% | 34.37% | 35.89% | 38.02% | Upgrade
|
Free Cash Flow Margin | 19.61% | 29.17% | 12.78% | 19.30% | 26.91% | 36.44% | Upgrade
|
EBITDA | 3,243 | 4,063 | 5,726 | 5,795 | 4,407 | 3,817 | Upgrade
|
EBITDA Margin | 33.74% | 38.65% | 42.72% | 43.89% | 43.65% | 45.78% | Upgrade
|
D&A For EBITDA | 580.56 | 518.06 | 464.6 | 378.64 | 308.36 | 233.32 | Upgrade
|
EBIT | 2,663 | 3,545 | 5,262 | 5,416 | 4,099 | 3,584 | Upgrade
|
EBIT Margin | 27.70% | 33.72% | 39.26% | 41.03% | 40.59% | 42.98% | Upgrade
|
Effective Tax Rate | 23.84% | 25.98% | 26.52% | 32.02% | 22.52% | 21.63% | Upgrade
|
Revenue as Reported | 10,248 | 11,133 | 13,867 | 14,126 | 10,240 | 8,519 | Upgrade
|
Advertising Expenses | - | 34.78 | 34.89 | 18.83 | 18.37 | 36.04 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.